Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?
Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional an...
- Autores:
-
Chávez-Castillo, Mervin
Ortega, Ángel
Cudris-Torres, Lorena
Duran, Pablo
Rojas, Milagros
Manzano, Alexander
Garrido, Bermary
Salazar, Juan
Silva, Aljadis
Rojas-Gomez, Diana Marcela
De Sanctis, Juan B.
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2021
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/8636
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/8636
https:// doi.org/10.3390/ijms221910370
https://www.mdpi.com/1422-0067/22/19/10370/htm
- Palabra clave:
- Chronic pain
Specialized pro-resolving lipid mediators
Inflammation
Long-term potentiation
Central nervous system sensitization
Polyunsaturated fatty acids
Eicosanoids
Nociception
Omega 3 fatty acids
Pain management
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
| Summary: | Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP. |
|---|